UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update

Lee, A; Waterhouse, J; Linch, M; (2020) Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update. EMJ Oncology , 8 (3) 10.33590/emj/20-00044. Green open access

[thumbnail of Lee_Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma- A 2020 Update_VoR.pdf]
Preview
Text
Lee_Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma- A 2020 Update_VoR.pdf - Published Version

Download (626kB) | Preview

Abstract

Advanced urothelial cancer (aUC) is invariably lethal and standard of care, platinum-based chemotherapy has changed little over the past 25 years. However, the past 5 years have been transformational with the advent of immunotherapies and targeted therapies. In this review, the authors focus on the therapies that are showing the greatest promise and have changed, or will imminently impact, the treatment landscape of aUC. Checkpoint inhibition is showing deep and durable responses in some patients and trial activity is concentrated on identifying the most suitable position within the treatment paradigm along with the most appropriate patients and therapeutic combinations. Novel targeted therapies in aUC are gaining renewed interest with nectin-4 antibody drug conjugates and fibroblast growth factor receptor inhibitors, both receiving recent regulatory approvals. Bispecific antibodies, capable of binding to two targets at the same time, are also showing promise. This review discusses the preclinical data, the relevant past, and present clinical trials along with regulatory status to provide a concise overview of the current and impending treatment options for aUC.

Type: Article
Title: Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update
Open access status: An open access version is available from UCL Discovery
DOI: 10.33590/emj/20-00044
Publisher version: https://doi.org/10.33590/emj/20-00044
Language: English
Additional information: © 2020 European Medical Group LTD. Published under a Creative Commons license (https://creativecommons.org/licenses/by-nc/4.0/).
Keywords: Antibody-drug conjugates (ADC), bispecific antibodies, bladder cancer, enfortumab vedotin (EV), fibroblast growth factor receptor (FGFR), immunotherapy, nectin-4, targeted therapies, urothelial cancer
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: https://discovery.ucl.ac.uk/id/eprint/10110435
Downloads since deposit
85Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item